NCT07383753 Virtual Hand-Arm Assessments for Children With Cerebral Palsy
| NCT ID | NCT07383753 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Holland Bloorview Kids Rehabilitation Hospital |
| Condition | Cerebral Palsy (CP) |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-10-22 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-10-22 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cerebral palsy (CP) affects approximately 1 in 500 Canadian children, and the majority experience hand and arm limitations that impact independence, participation in daily activities, and overall quality of life. Many children require ongoing clinical assessments and therapy delivered in specialized centres, creating significant burden related to travel, scheduling, and interruptions to school and work. Barriers such as geography, socioeconomic factors, and pandemic-related service disruptions have further limited equitable access to in-person care. Although virtual care has expanded rapidly and families have expressed strong interest in hybrid care models, there is currently no validated approach for conducting comprehensive virtual hand-arm assessments for children with CP. Virtual administration of standardized assessments, individualized goal-based evaluations, and naturalistic observation tools has not been systematically studied. Evidence is urgently needed to determine which assessments can be administered virtually, how acceptable and feasible they are for families, and whether virtual and in-person assessment methods produce equivalent results.
Eligibility Criteria
Inclusion Criteria: * Have a diagnosis of Cerebral Palsy * Are between 6 to 17 years old with sufficient cognitive capacity and cooperation to sit without a break for 30 minutes at a time * MACS levels I (handles objects easily) to III (handles objects with difficulty) * No visual limitations that would interfere with video conferencing * Has a caregiver willing to participate and can questions about preferences * Have an appropriate device and internet access for video conferencing Exclusion Criteria: \- Active treatments (e.g. Botulinum Toxin injections or constraint therapy in the last two months, or upper extremity surgery in the last 6 months) that might impact upper limb function stability over the study period.
Contact & Investigator
Elaine Biddiss, PhD
PRINCIPAL INVESTIGATOR
Holland Bloorview Kids Rehabilitation Hospital, Bloorview Research Institute
Frequently Asked Questions
Who can join the NCT07383753 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 17 Years, studying Cerebral Palsy (CP). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07383753 currently recruiting?
Yes, NCT07383753 is actively recruiting participants. Contact the research team at ssert@hollandbloorview.ca for enrollment information.
Where is the NCT07383753 trial being conducted?
This trial is being conducted at Ajax, Canada, Ottawa, Canada, Toronto, Canada.
Who is sponsoring the NCT07383753 clinical trial?
NCT07383753 is sponsored by Holland Bloorview Kids Rehabilitation Hospital. The principal investigator is Elaine Biddiss, PhD at Holland Bloorview Kids Rehabilitation Hospital, Bloorview Research Institute. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.